Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

卡培他滨 拉帕蒂尼 医学 曲妥珠单抗 转移性乳腺癌 肿瘤科 内科学 乳腺癌 药理学 癌症 随机对照试验 结直肠癌
作者
Fei Ma,Quchang Ouyang,Wěi Li,Zefei Jiang,Zhongsheng Tong,Yunjiang Liu,Huiping Li,Shiying Yu,Jifeng Feng,Shusen Wang,Xichun Hu,Jianjun Zou,Xiaoyu Zhu,Binghe Xu
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:37 (29): 2610-2619 被引量:352
标识
DOI:10.1200/jco.19.00108
摘要

PURPOSE Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy and tolerability of pyrotinib versus lapatinib, both in combination with capecitabine, in women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer in an open-label, multicenter, randomized phase II study. PATIENTS AND METHODS Chinese patients with HER2-positive relapsed or metastatic breast cancer previously treated with taxanes, anthracyclines, and/or trastuzumab were assigned (1:1) to receive 400 mg pyrotinib or lapatinib 1,250 mg orally once per day for 21-day cycles in combination with capecitabine (1,000 mg/m 2 orally twice per day on days 1 to 14). The primary end point was investigator-assessed overall response rate per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. RESULTS Between May 29, 2015, and March 15, 2016, 128 eligible patients were randomly assigned to the pyrotinib (n = 65) or lapatinib (n = 63) treatment groups. The overall response rate was 78.5% (95% CI, 68.5% to 88.5%) with pyrotinib and 57.1% (95% CI, 44.9% to 69.4%) with lapatinib (treatment difference, 21.3%; 95% CI, 4.0% to 38.7%; P = .01). The median progression-free survival was 18.1 months (95% CI, 13.9 months to not reached) with pyrotinib and 7.0 months (95% CI, 5.6 to 9.8 months) with lapatinib (adjusted hazard ratio, 0.36; 95% CI, 0.23 to 0.58; P < .001). The most frequent grade 3 to 4 adverse events were hand-foot syndrome in 16 of 65 patients (24.6%) in the pyrotinib group versus 13 of 63 (20.6%) in the lapatinib group; diarrhea in 10 patients (15.4%) versus three patients (4.8%), respectively; and decreased neutrophil count in six patients (9.2%) versus two patients (3.2%), respectively. CONCLUSION In women with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines, and/or trastuzumab, pyrotinib plus capecitabine yielded statistically significant better overall response rate and progression-free survival than lapatinib plus capecitabine in this randomized phase II trial.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
木兮发布了新的文献求助10
刚刚
yang发布了新的文献求助10
1秒前
www2完成签到,获得积分20
1秒前
呆萌的豌豆完成签到,获得积分10
1秒前
润华发布了新的文献求助10
1秒前
ding的应助被香香香采纳,获得10
2秒前
诸糜完成签到,获得积分10
2秒前
iieee完成签到,获得积分10
2秒前
zclm发布了新的文献求助10
2秒前
南宫誉完成签到,获得积分10
2秒前
华北临时工完成签到,获得积分10
2秒前
隐形曼青的应助被霁月采纳,获得10
2秒前
3秒前
3秒前
4秒前
zbw发布了新的文献求助10
4秒前
霍则风发布了新的文献求助10
4秒前
思源的应助被Yoona采纳,获得10
5秒前
syvshc的应助被能能姓徐采纳,获得10
5秒前
打打的应助被Han采纳,获得10
5秒前
5秒前
怕孤独的向日葵完成签到,获得积分10
6秒前
6秒前
Owen的应助被诗酒梦芳华采纳,获得10
6秒前
6秒前
诸糜发布了新的文献求助10
7秒前
7秒前
打打的应助被开心德地采纳,获得10
7秒前
扶苏完成签到,获得积分10
8秒前
8秒前
霍则风发布了新的文献求助20
8秒前
隐形曼青的应助被WMY采纳,获得10
8秒前
sxy发布了新的文献求助10
9秒前
9秒前
半三月完成签到,获得积分10
9秒前
9秒前
找到了没完成签到,获得积分10
9秒前
leo发布了新的文献求助10
9秒前
向晚发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187748
求助须知:如何正确求助?哪些是违规求助? 9575825
关于积分的说明 21843288
捐赠科研通 7785628
什么是DOI,文献DOI怎么找? 3435097
关于科研通互助平台的介绍 2559495
邀请新用户注册赠送积分活动 2482000